InMed $IN Names Mauro Maccarrone to Advisory Board

InMed Pharma(CSE: IN; OTCQB: IMLFF)

InMed Pharmaceuticals Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce the addition of Dr. Mauro Maccarrone to its Scientific Advisory Board.

Dr. Mauro Maccarrone is Professor and Chair of Biochemistry and Molecular Biology at Campus Bio-Medico, University of Rome. He also serves as Director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome.  Prof. Maccarrone served as the President of the International Cannabinoid Research Society and was the recipient of their 2016 Mechoulam Award. He also served as Chair of the 2015 Gordon Research Conference on Cannabinoid Function in the CNS, and is a founding member of the European Cannabinoid Research Alliance. In addition to having authored over 460 published papers. Dr. Maccarrone serves as referee or on the editorial boards to numerous scientific journals, including ScienceNature MedicineJAMAPNASBloodBrainJournal of NeuroscienceFrontiers in Molecular NeuroscienceCannabinoids and Cannabinoid Research . He is also Editor of Biochemistry for the Encyclopedia of Life Sciences.

“InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs.  One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their in-depth knowledge to help advance our products. We are very pleased to add Dr. Mauro Maccarrone and his vast experience in the field of cannabinoid research as an integral part of our Scientific Advisory Board. We look forward to working with Dr. Maccarrone to help bring drug therapies to those in need.”

-Dr. Sazzad Hossain, InMed’s Chief Scientific Officer

“It is with pleasure that I accepted the invitation of InMed to join its Scientific Advisory Board to begin a new collaboration that will be a mutually beneficial endeavor and expand my own research horizons. Together with InMed’s scientific team, we are looking forward to shortening the path from basic science to tomorrow’s medicine on a number of innovative projects.”

-Dr. Maccarrone, InMed’s Advisory Board